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Human placental (hPLAP) and germ cell (PLAP-like) alkaline phosphatases are polymorphic and heat-stable enzymes. This study
was designed to develop speciﬁc immunoassays for quantifying hPLAP and PLAP-like enzyme activity (EA) in sera of cancer
patients, pregnant women, or smokers. Polyclonal sheep anti-hPLAP antibodies were puriﬁed by aﬃnity chromatography with
whole hPLAP protein (ICA-PLAP assay) or a synthetic peptide (aa 57–71) of hPLAP (ICA-PEP assay); the working range was 0.1–
11U/L and cutoﬀ value was 0.2U/L EA for nonsmokers. The intra- and interassay coeﬃcients of variation were 3.7%–6.5% (ICA-
PLAP assay) and 9.0%–9.9% (ICA-PEP assay). An insigniﬁcant cross-reactivity was noted for high levels of unheated intestinal
alkaline phosphatase in ICA-PEP assay. A positive correlation between the regression of tumor size and EA was noted in a child
with embryonal carcinoma. It can be concluded that ICA-PEP assay is more speciﬁc than ICA-PLAP, which is still useful to detect
other PLAP/PLAP-like phenotypes.
Copyright © 2006 S´ ervio T. Stinghen et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Human alkaline phosphatases (ALP) are dimeric enzymes
anchored by glycosylphosphatidylinositol to the cell mem-
brane. Speciﬁc phospholipases can cleave ALP from the cell
membrane, producing free ALP in the serum [1–3]. ALP
consists of a family of four isozymes: (1) placental ALP
(PLAP; or hPLAP in the case of human placental ALP), and
(2) germ cell ALP (PLAP-like or GCAP), which are both sta-
ble at 65◦Ca n dp r e s e n t9 8 %h o m o l o g y ;a sw e l la s( 3 )i n -
testinal ALP (IAP), and (4) nonspeciﬁc tissue ALP (TNAP)
or liver/bone/kidney ALP, which are not stable at 65◦Ca n d
present 88% and 56% homology with PLAP, respectively [4–
6].
PLAP is encoded by a highly polymorphic gene of which
3 common alleles and at least 18 rare alleles exist; giving
origin to 48 known phenotypes [7–9]. The PLAP-like en-
zyme is encoded by 4 alleles with at least 10 known pheno-
types [9–12]. PLAP and PLAP-like enzymes may form het-
erodimers [13].
PLAP is synthesized in the placental syncytiotrophoblast
starting after the 12th week of pregnancy [14] and is prob-
ably involved in transplacental IgG transport [15, 16]. The
PLAP-like enzyme is primarily synthesized in testis, cervix,
and thymus. Trace amounts are synthesized in placenta and
lung tissues [17, 18]. In healthy, nonsmoking adults PLAP
and PLAP-like enzyme activities represent less than 1% of all
ALP [19, 20]. Smoking causes elevated serum concentrations2 Journal of Biomedicine and Biotechnology
of the PLAP-like enzyme, which may diminish the value of
PLAP-like enzyme as a tumor marker. Serum concentrations
of PLAP-like enzyme return to the normal range after 1-2
months of smoking cessation [21–23].
Ectopic expression of PLAP is associated with cancer
of ovary, testis, lung, and colorectal tract [14]. Ectopic ex-
pression of the PLAP-like enzyme is associated with testic-
ular cancers: intratubular germ cell neoplasia, unclassiﬁed
(IGCNU), seminoma, embryonal carcinoma, and chorio-
carcinoma [23–25]. Roelofs et al [26] using RT-PCR have
shown that seminoma and IGCNU express predominantly
the PLAP-like enzyme, while embryonal carcinomas express
variable amounts of PLAP and PLAP-like enzymes.
Due to their high homology, PLAP and PLAP-like en-
zymes cannot be easily distinguished using polyclonal or
monoclonal antibodies. However, the speciﬁc monoclonal
antibodies C2 and 17E3 may recognize only PLAP [27, 28].
In general, the enzyme activity is usually considered to in-
clude both PLAP and PLAP-like.
Elevated serum concentrations of PLAP and PLAP-like
enzymes were found in 25%–65.5% of patients with ovar-
ian cancer [19, 29–35], and 22%–89% of patients with tes-
ticular neoplasms [23, 36–42]. Variable values of PLAP and
PLAP-like enzyme activity or serum concentrations may de-
pend upon the method and antibody used for detection, as
well as upon cancer type or staging. Seminomas can have a
similar molecular proﬁle to embryonal carcinoma; explain-
ing aberrant immune proﬁles [43].
Testing of serum samples from ovarian cancer patients
demonstrated that testing for PLAP/PLAP-like enzyme ac-
tivity is less sensitive than testing for CA 125 (71%–85%)
andalpha-fetoprotein(AFP)(88%)[44];however,testingfor
PLAP/PLAP-like enzyme activity was considered to be the
best survival indicator [35], and more speciﬁc (PLAP/PLAP-
like; 95%) than CA 125 (71%) [31]. Weissbach et al [23]
have demonstrated that serum PLAP/PLAP-like was more
sensitive (56%) than other tumor markers, such as HCG
(35%) and LDH (34%), in the evaluation of seminoma pa-
tients.
Polyclonal antibodies against PLAP and PLAP-like en-
zymes may cross-react with IAP isozyme. In contrast, mon-
oclonal antibodies may not detect all ALP phenotypes if the
epitope is absent (eg, because of polymorphism, or if it has
been cleaved by phospholipases) [45, 46].
To eliminate both of these latter problems, this research
was designed to develop and test two sensitive and speciﬁc
immunoassaysforPLAPandPLAP-likeenzymeactivitiesus-
ing two sheep anti-hPLAP polyclonal antibodies puriﬁed by
aﬃnity chromatography.
MATERIALS AND METHODS
Animalimmunization
One adult sheep was immunized with hPLAP (Sigma-
Aldrich, St Louis, Mo, USA) through seven subcutaneous in-
jections at 14-day intervals. The emulsion for the ﬁrst injec-
tion was prepared using 2mg of hPLAP dissolved in 1mL
of 0.05M phosphate buﬀered saline (PBS; pH 7.4) and 1mL
of Freund’s complete adjuvant (Sigma-Aldrich, St Louis, Mo,
USA). The remaining 6 injections were prepared using Fre-
und’s incomplete adjuvant.
Optimal animal immunization was indicated by high
serum concentration of anti-hPLAP. This was measured
by two diﬀerent protocols: double immunodiﬀusion test
and indirect ELISA. Animal sera were obtained (0.8L)and
immunoglobulins were precipitated in a saturated ammo-
nium sulfate solution.
Puriﬁcationofanti-hPLAPantibodies
Speciﬁc anti-hPLAP antibodies were puriﬁed through an af-
ﬁnity chromatography column. One gram of cyanogen bro-
mide-activated Sepharose (CNBr-Sepharose; Sigma-Aldrich,
St Louis, Mo, USA) was coupled to 20mg of hPLAP accord-
ing to previously described protocols [47].
Aliquots of sheep immunoglobulins were dissolved in
PBS and circulated through the column at a ﬂow rate
of 20mL/h overnight at 4◦C. Afterwards, the column was
washed with PBS until absorbance (280nm) of the eluted
solution had returned to baseline. Recovery of the immuno-
globulins bound to the hPLAP-Sepharose column was per-
formed by washing the column with 0.1M glycine-HCL,
0.15M NaCl, pH 2.8, until an immunoglobulin peak was ob-
tained.Finally,thecolumnwaswashedwithPBSuntiltheab-
sorbance returned to baseline. The eluted solution contain-
ing anti-hPLAP antibodies was dialyzed overnight at 4◦Ci n
PBS.
Puriﬁcationofanti-aminoacid57–71peptide
A synthetic peptide extending from amino acid (aa) residue
57 to 71 of hPLAP, made by a technique reported by Kates
and Albericio [48], was generously synthesized and provided
by the Biophysics Laboratory from UNIFESP (S˜ ao Paulo,
SP). Selected peptide aa 57–71 of hPLAP diﬀers in 2 residues
from PLAP-like, 3 residues from IAP, and 9 residues from
TNAP [6]. This peptide sequence was chosen because it con-
tains free epitope(s) in an unfolded loop and accessible to
antibodies.
Thesyntheticpeptide(22.9mg)wasimmobilizedto1.0g
of CNBr-Sepharose according to previously described meth-
ods [47]. Aliquots containing puriﬁed anti-hPLAP antibod-
ies were circulated through the Sepharose-aa 57–71 peptide
column at a ﬂow rate of 20mL/h. Unbound anti-hPLAP an-
tibodies (PLAP-Ab) that did not recognize the aa 57–71 pep-
tidewereelutedandseparatedtopreparetheﬁrstimmunoas-
say, which was named ICA-PLAP. Anti-aa 57–71 peptide an-
tibodies (PEP-Ab) were eluted and collected as described
above. These antibodies were separated to prepare the sec-
ond immunoassay, called ICA-PEP.
Standardcurve
Puriﬁed hPLAP (11U/mg) (Sigma-Aldrich, St Louis, MO,
USA),3g/Lindistilledwater,wasusedasacontrol,dilutedinS´ ervio T. Stinghen et al 3
0.25% casein, 0.05% Tween 20, and PBS (dilution buﬀer) to
obtain hPLAP activities ranging from 0.17–11U/L. Dilution
buﬀer was used as a zero standard solution.
Speciﬁcity
ThepuriﬁedIAP(3U/mg)(Calzyme,SanLuisObispo,Calif,
USA), 1g/L in distilled water, was used to determine cross-
reactivity. It was diluted in dilution buﬀer at concentrations
of 0.05–55U/L. IAP samples were tested with and without
heat treatment at 65◦Cf o r1 0m i n u t e s .
Serumsamples
Subjects(smokersandnonsmokers)
This study was approved by the Ethics Committee at the
Hospital of Clinics of the Federal University of Paran´ a, and
samples from serum or tissue were obtained after consent
from patients or the patients’ parents. Control serum spec-
imens were obtained from 100 healthy adults: 93 serum sam-
ples from blood donors representing negative controls (19–
57 years of age; 39 females and 54 males; 44 nonsmokers and
49 smokers), and 7 serum samples from 7 pregnant women
representing positive controls (24–35 years of age; at 12–37
weeks of gestation). Social smokers (1-2 cigarettes per week)
or subjects who smoke less than 1 cigarette per day were not
included in this study.
Achildwithembryonalcarcinoma(casereport)
An 11.2-year-old girl was admitted to the hospital complain-
ing of abdominal pain for the last 2 months. On admis-
sion she presented with an enlarged abdominal volume due
to a palpable mass in the lower third of the abdomen. Her
height was 141cm and body weight was 26kg; 5kg less than
2 months before admission. There was no record of cancer
among her relatives. A CT scan revealed an 11 × 12 × 16cm
extragonadal mass located between the bladder and the rec-
tum, extending up to the mesogastrium, at the level of L4.
Histological evaluation and immunohistochemistry of tu-
mor specimens obtained from the biopsy were positive for
CKAE1/AE3 (multifocal) and Ki67 (90%), and was nega-
tive for AFP, LCA, and CD30 markers, suggesting it to be
an embryonal carcinoma at Stage III. Serum samples for
PLAP/PLAP-like enzyme activity were collected before, dur-
ing, and after chemotherapy.
Placentalanalysis(positivecontrol)
A tissue sample from a term placenta was obtained and used
asapositivecontrol.Allsamples(seraandtissue)werestored
at −80◦C until assay. Soluble tissue extracts were obtained as
previously described [21].
Immunoassays:ICA-PLAPandICA-PEP
A 96-well Nunc MaxiSorp microplate (Nalge Nunc Inter-
national, Roskilde, Denmark) was coated overnight at 4◦C
with 100µLo fa1 .6µg/mL solution of anti-hPLAP antibod-
ies (ICA-PLAP assay), or an 18.4µg/mL solution of anti-aa
57–71 peptide antibodies (ICA-PEPassay)in 0.05Mcarbon-
ate buﬀer, pH 9.6. Afterwards, the wells were washed twice
with wash buﬀer (0.05% Tween 20 in saline). Each well was
ﬁlled with 100µL of blocking buﬀer (2% casein in PBS) and
the plate was incubated for 1 hour at 37◦C. After washing
twice with wash buﬀer, 100µL of a standard solution con-
taining hPLAP (0–11U/L, range of the standard curve) in
dilution buﬀer (0.25% casein, 0.05% Tween 20, PBS), and
100µL of experimental serum sample, or of homogenized
tissue supernatant, were added to the wells. After incuba-
tion for 1 hour at 37◦C, the plate was washed 5 times with
wash buﬀer and 100µL p-nitrophenyl phosphate substrate
wasadded.Afterincubationfor5hours(ICA-PLAPassay)or
overnight (ICA-PEP assay) at 37◦C, the enzymatic reaction
wasstoppedthroughtheadditionof50µLof3MN aOH.The
absorbance (405/620nm) was measured using a microplate
reader (Spectra, Tecan, Zurich, Switzerland). All standards
andsamplesweretestedinduplicate.Thepositivecontrolfor
all assays was a pool of sera taken from 5 pregnant women
and 1 placental extract. Positive samples were retested after
heat treatment at 65◦C for 10 minutes in order to inactivate
IAP.
RESULTS
Production,puriﬁcation,andtitrationofantibodies
SerumfromhPLAP-immunizedsheepwastestedbyimmun-
odiﬀusion in the presence of hPLAP (1mg/mL), and the re-
sults were positive up to 1 : 2 dilutions. After treatment the
animal was given one extra injection of hPLAP. Serum titers
were reanalyzed by indirect ELISA 2 weeks later, when ade-
quate immunization was revealed by titers of 1 : 256000.
Puriﬁed polyclonal antibodies by Sepharose-hPLAP had
a ﬁnal concentration of 1.6g/L, whereas puriﬁed polyclonal
antibodies by Sepharose-aa 57–71 peptide had a ﬁnal con-
centration of 0.92g/L.
Immunoassaycharacteristics
The standard curve was linear between 0.1U/Land11U/L
(Figure 1), and the detection limit (deﬁned as the mean +4
SD of the absorbance of the zero standard for ALP) was
0.1U/L, for both ICA-PLAP and ICA-PEP assays.
The intra- and interassay variability (n = 12) was as-
sessed by measuring 2 pregnant serum pools with a mean
PLAP activity of 5.5a n d0 .75U/L for ICA-PLAP, and 4.8a n d
0.98U/L for ICA-PEP. The mean intra- and interassay CV
were 6.5% and 9.9%, respectively, for the ICA-PLAP assay,
and 3.7% and 9%, respectively, for the ICA-PEP assay.
Cross-reactionsintheICA-PLAPassaywerenotedatIAP
concentrations of 55U/L and 27.5U/L, exhibiting activity of
1.22U/L and 0.75U/L, respectively. At IAP concentrations
55U/L, the activity for the ICA-PEP assay was 0.4U/L.No
cross-reactivity was noted for heated IAP in either assay;
showing that IAP is very sensitive to high temperature.4 Journal of Biomedicine and Biotechnology
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Figure 1: Representative standard curve for the (a) ICA-PLAP and (b) ICA-PEP assays.
Resultsfromserumblooddonors
Average hPLAP/PLAP-like activity for nonsmoker blood
donors was 0.06 ± 0.12U/L (mean ± SD), using the ICA-
PLAP assay, and 0.01 ±0.04U/L (mean ± SD) with the ICA-
PEP assay. Smokers had hPLAP/PLAP-like enzyme activities
ranging from 0-1.72U/L, with a mean activity of 0.36 ±
0.41U/L (mean ± SD), as determined by the ICA-PLAP as-
say, and activities from 0-1.65U/L, with a mean activity of
0.25 ± 0.36U/L (mean ± SD), using the ICA-PEP assay.
Figure 2 shows the distribution of serum hPLAP/PLAP-like
activitiesfromblooddonorsmeasuredbytheICA-PLAPand
ICA-PEP assays.
The correlation between the ICA-PLAP and ICA-PEP re-
sults in blood donors was high (n = 93, r = 0.94), sup-
porting a rationale for the use of both assays. Heat inacti-
vation did not interfere with hPLAP/PLAP-like activity for
nonsmoker or smoker blood donors in either assay.
The hPLAP/PLAP-like enzyme activity cutoﬀ value—
deﬁned as the 90th percentile for the ICA-PLAP assay and
the 100th percentile for the ICA-PEP assay—for nonsmok-
ers was 0.2U/L for both assays. Based on the present data, we
propose a normal hPLAP/PLAP-like enzyme activity cutoﬀ
value ranging from 0–0.4U/L for smokers, but further anal-
yses are necessary to conﬁrm this threshold.
Pregnantseraresults
Serum samples from 7 pregnant patients were measured
without heating (NI) and after heat inactivation (I). hPLAP
activities ranged from 0.1–53U/L. The pregnant patient at
the 12th week of gestation had very low hPLAP activity.
The pregnant patient at the 18th week of gestation had low
hPLAP activity (1.58–2.5U/L). Patients from the 27th week
to the 37th week of gestation had hPLAP activities that
ranged from 31–53U/L (Table 1). There were no diﬀerences
identiﬁed in hPLAP activities when comparing inactivated
and noninactivated samples using either the ICA-PLAP or
ICA-PEP assays.
Casereport
The 11.2-year-old patient with ovary embryonal carcinoma
was admitted with a visible and palpable abdominal mass.
Before chemotherapy (4 cycles of Ifosfamide and cisplatin,
at intervals of 21 days), NI and I serum samples had
hPLAP/PLAP-like enzyme activity of 9.5U/Land10.2U/L,
respectively, in the ICA-PLAP assay, and 9.3U/L (NI and
I serum) in the ICA-PEP assay. On the 7th day after ﬁrst
cycle of chemotherapy the mass was palpable but not vis-
ible anymore, and hPLAP/PLAP-like activity in serum was
5.7U/L(NI)and5.6U/L (I), respectively, in the ICA-PLAP
assay, and 5.7U/L(NI)and5.3U/L (I) in the ICA-PEP as-
say. On the 14th day after ﬁrst cycle of chemotherapy the ab-
dominal mass was not palpable anymore and hPLAP/PLAP-
like activity in serum was 0.23U/L (NI) and 0.25U/L (I),
respectively, in the ICA-PLAP assay, and 0.25U/L (NI and
I) in the ICA-PEP assay. Forty-two days after initiating
chemotherapy a CT scan showed evidence of complete
tumor regression, and the hPLAP/PLAP-like enzyme ac-
tivity in serum was stable; exhibiting 0.22U/L (NI) and
0.20U/L (I), respectively, for ICA-PLAP, and 0.23U/L (NI)
and 0.22U/L (I) for ICA-PEP. hPLAP/PLAP-like enzyme ac-
tivity in serum was undetectable, 210 days following initia-
tionofchemotherapy(Figure 3).After4cyclesofchemother-
apy (ifosfamide/CDDP/VP16) complete tumor regression
was conﬁrmed using imaging analysis, exploratory surgery,
and histological analysis.S´ ervio T. Stinghen et al 5
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Figure 2: Distribution of hPLAP/PLAP-like activity in serum of blood donors grouped according to smoking habits (n = 93) for (a) ICA-
PLAP and (b) ICA-PEP assays.
Table 1: hPLAP activities in noninactivated (NI) and heat-inactivated (I) pregnant serum measured by ICA-PLAP and ICA-PEP.
Serum sample Patient age (years) Time of pregnancy (weeks) ICA-PLAP hPLAP (U/L) ICA-PEP hPLAP (U/L)
N IIN I I
13 5 1 2 0 .10 .10 .10 .2
23 3 1 8 1 .58 1.72 2 .5
32 8 2 7 3 3 3 5 .53 6 3 5 .5
42 6 3 2 3 1 3 1 3 4 3 2
52 4 3 3 5 1 .54 9 5 35 2
53 2 3 5 4 2 4 4 4 0 .24 3
62 7 3 7 4 3 4 2 4 1 4 4
DISCUSSION
Immunoassays for hPLAP using monoclonal or polyclonal
antibodies generally do not distinguish PLAP from PLAP-
like enzymes because of the high homology between these
isoforms [6]. Polyclonal antibodies raised against PLAP may
cross-react with IAP [29, 49] but this can be minimized
by serum heat inactivation. Monoclonal antibodies may not
detect hPLAP/PLAP-like enzyme activity if the epitope is not
present in the polymorphic protein [7, 45, 46]. The hPLAP
enzyme is more polymorphic (at least 48 phenotypes) than
the PLAP-like enzyme (10 phenotypes) [8, 9, 11, 12].
Two cost-eﬀective, speciﬁc, and sensitive immunoassays
were developed for determining hPLAP/PLAP-like enzyme6 Journal of Biomedicine and Biotechnology
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Figure 3: hPLAP/PLAP-like activities in the sera of a 11.2-year-old child with embryonal carcinoma measured by (a) ICA-PLAP and (b)
ICA-PEP assays. Forty-two days after initiating chemotherapy a CT scan revealed evidence of complete tumor regression.
activity. Two polyclonal antibodies were selected by aﬃnity
chromatography;onePLAP-Abthatiscapableofrecognizing
most PLAP/PLAP-like epitopes that are not recognized by
monoclonal antibodies, and a second antibody (PEP-Ab)
used in the ICA-PEP that recognizes the aa 57–71 sequence
of hPLAP. PLAP/PLAP-like activity determined by PLAP-
Ab was, as expected, inferior to PEP-Ab, suggesting that the
second antibody may present monoclonal characteristics. A
substitution of 1 amino acid in an antigen may modify the
antibody-binding activities [28]. The synthetic peptide used
in this study diﬀers in 3 amino acids from IAP and 9 amino
acids from TNAP [6], and had 15 amino acid residues (the
minimum necessary to build an epitope that may comprise
15–22aminoacidresidues[50]);suggestingthatPEP-Abrec-
ognizes PLAP speciﬁc epitope(s).
The sensitivity for both ICA-PLAP and ICA-PEP assays
was 0.1U/L; similar to observations in studies that used anti-
hPLAPmonoclonalantibodies[31,51].Cross-reactivitywas
observed for high levels of IAP (27.5U/Land55U/L)inthe
ICA-PLAP and ICA-PEP assays, respectively. This interfer-
ence could be abolished when IAP was inactivated by heat-
ing. The ICA-PLAP and ICA-PEP assays were highly cor-
related (r = 0.94). The ICA-PLAP assay is less speciﬁc,
but more cost-eﬀective than ICA-PEP. Although ICA-PEP
was capable of recognizing similar PLAP/PLAP-like activ-
ity in heated and unheated samples, ICA-PLAP would re-
veal other PLAP/PLAP-likephenotypes in unheated samples.
Taken together, a combined assay using each of the anti-
bodies may minimize the disadvantage of using monoclonal
and polyclonal antibodies. For instance, hPLAP/PLAP-like
activity in unheated serum samples from 5 nonsmokers was
found slightly above (≤ 0.6U/L)cutoﬀ value (0.2U/L)only
in the ICA-PLAP assay, suggesting that these ﬁndings were
due to cross-reaction with IAP; as described in other studies
[29, 49]. IAP activity in serum is related to diet and blood
group status [52].
Our data show that the normal serum value for PLAP/
PLAP-like enzyme activity in adult nonsmokers is around
0.2U/L. A normal Gaussian distribution of hPLAP/PLAP-
like enzyme activity was not observed in serum of healthy
individuals who smoked. Such heterogeneity among these
individuals and the resulting high standard deviation in av-
erage values have been reported in previous studies [39, 51].
In the literature, PLAP activity in lung tissue was reported
to correspond to PLAP activity in placenta, while PLAP in
serumofsmokerswasreportedasPLAP-likeactivity[21,51];
this discrepancy is not well understood. The proposed cut-
oﬀ corresponding to hPLAP/PLAP-like ﬁndings in serum of
smokers without cancer in this study was 0.4U/L,however ,
this must be better evaluated with serial sampling and while
considering the clinical status of the individual. PLAP/PLAP-
like enzyme activity measured in serum of smokers proba-
bly originates from the lungs (pneumocytes), where cellular
damage caused by cigarette smoke may release PLAP-like en-
zymes into the blood [21, 39], possibly in proportion to the
duration and intensity of smoking [39, 53].
PLAP activity in serum samples from pregnant patients
measured by ICA-PLAP and ICA-PEP assays showed no dif-
ference between heat-inactivated and noninactivated sam-
ples, indicating that the circulating protein is mostly PLAP
released by the placenta. As expected, hPLAP activity in-
creased linearly with the advance of pregnancy, as the pla-
centalsyncytiotrophoblastproduceshighPLAPlevelsduring
the 27th to 37th weeks of gestation. This relationship sug-
gests that the monitoring of hPLAP activity could be used as
an additional tool to evaluate placenta viability.
Since PLAP/PLAP-like activity could be detected at very
low levels in early stages of pregnancy and in smoking in-
dividuals, the developed assays could also be used to de-
tect PLAP/PLAP-like activity in the serum of cancer pa-
tients. In fact, this immunoassay was possible and extremely
useful in the follow-up of a young female patient withS´ ervio T. Stinghen et al 7
embryonal carcinoma. Following the ﬁrst cycle of chem-
otherapy, PLAP/PLAP-like serum activity decreased in pro-
portion to the size of tumor. This suggests that the im-
munoassay of PLAP/PLAP-like serum activity may be a
good marker for monitoring response to chemotherapy or
eventual cancer recurrence, minimizing the need for exhaus-
tive imaging analyses. To further validate PLAP/PLAP-like
serum activity as a tumor marker, more serum samples from
patients with cancer are necessary. As reported by other au-
thors, increased levels of PLAP/PLAP-like were observed in 2
patients with recurrent testicular seminoma 2 months before
d e t e c t i o nb yC Ts c a n[ 42]. The longest interval found be-
tween increased levels of PLAP/PLAP-like and posterior can-
cer detection by imaging analysis was 2 years in a woman
with a very small ovarian cancer [54]. Determination of
PLAP/PLAP-like activity using immunoassays could be par-
ticularly useful for serum of patients with testicular cancer
and ovarian carcinomas, as is the case for more sensitive
markers such as CA 125 and AFP. In fact, PLAP/PLAP-like
activity seems to be more speciﬁc than CA 125 and AFP [31].
HCGandAFPareusedastumormarkersfornonseminoma-
toustesticularcancer,butPLAP/PLAP-likeactivityisthebest
tumor marker for the follow-up of patients with seminomas
[39].
The ICA-PLAP and ICA-PEP immunoassays could be
explored to detect hPLAP/PLAP-like activity above 0.2U/L
(cutoﬀ value in adults) in physiological and pathological
conditions, especially in patients with embryonal cancer or
other types of cancer reported in other studies (testis, ovary,
lung, and colorectal tract). Furthermore, it can be concluded
that ICA-PEP assay is more speciﬁc than ICA-PLAP, which is
still useful to detect other PLAP/PLAP-like phenotypes that
eventually may not be detected by ICA-PEP. Heating inacti-
vationofsamplesmayeliminateIAPandotheralkalinephos-
phatase activity and eventually also decrease PLAP/PLAP-
like activity, but this unwished eﬀect could be conﬁrmed by
testing unheated samples in the ICA-PEP assay.
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